Long-Term Benefits of Continuous Glucose Monitoring Combined with Insulin Pump Therapy

Rukhsana Zulfiqar; Komal Abbas; Saeeda Khan; Kanwal Fatima; Adnan Manzoor; Muhammad Awais

doi:10.70749/ijbr.v2i02.264

Authors

Rukhsana Zulfiqar Sohail University, Jinnah College of Nursing, Karachi, Sindh, Pakistan.
Komal Abbas PIMS Hospital, Islamabad, Pakistan.
Saeeda Khan Faculty of Nursing and Midwifery, Ziauddin University, Karachi, Sindh, Pakistan.
Kanwal Fatima School of Nursing and Midwifery, Aga Khan University, Karachi, Sindh, Pakistan.
Adnan Manzoor Department of General Medicine, Saidu Group of Teaching Hospitals, Swat, KP, Pakistan.
Muhammad Awais Department of General Medicine, Saidu Group of Teaching Hospitals, Swat, KP, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v2i02.264

Keywords:

CGM, Insulin Pump, Diabetes, Glycemic Control, Quality of Life

Abstract

Objective: To evaluate the long-term efficacy and safety of continuous glucose monitoring (CGM) combined with insulin pump therapy, focusing on glycemic control, patient adherence, quality of life, and reduction in diabetes-related complications. Methodology: A prospective cohort study was conducted on 100 patients with type 1 or insulin-dependent type 2 diabetes from February 2023 to July 2024 at a Tertiary Care Hospital in Karachi. Participants, aged 18–75 years, used CGM-integrated insulin pump therapy. Key metrics included HbA1c levels, time-in-range (TIR), adherence rates, and quality-of-life scores assessed at baseline and study completion. Statistical analyses were performed using SPSS, with significance set at p < 0.05. Results: The mean HbA1c level decreased to 8.14% (SD: 0.83, p = 0.003), while TIR improved to 67.90% (SD: 12.57, p = 0.001). Adherence rates were high, averaging 89.81% (SD: 5.62, p = 0.02), reflecting strong patient engagement. Quality-of-life scores also increased significantly, with a mean score of 79.74 (SD: 11.28, p = 0.015). No severe adverse events were reported, underscoring the safety of the intervention. Conclusion: CGM combined with insulin pump therapy significantly improves long-term glycemic control, adherence, and quality of life in diabetes management. These findings highlight the clinical and psychosocial benefits of integrating these technologies, particularly in achieving sustainable outcomes. Future research should explore broader population impacts, cost-effectiveness, and advanced technological integration

Downloads

Download data is not yet available.

References

Charleer, S., De Block, C., Nobels, F., Radermecker, R. P., Lowyck, I., Mullens, A., Scarnière, D., Spincemaille, K., Strivay, M., Weber, E., Taes, Y., Vercammen, C., Keymeulen, B., Mathieu, C., & Gillard, P. (2020). Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study. Diabetes Care, 43(12), 3016–3023. https://doi.org/10.2337/dc20-1531

Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., Davis, G., Kruger, D., Bhargava, A., Young, L., McGill, J. B., Aleppo, G., Nguyen, Q. T., Orozco, I., Biggs, W., & Lucas, K. J. (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. JAMA, 325(22), 2262–2272. https://doi.org/10.1001/jama.2021.7444

O'Meara, M., Acuña, J. C. M., & Uribe, A. (2023). Long-Term Benefits of an Integrated Continuous Glucose Monitoring and Insulin Pump System for Emergency Admissions, Hospitalization, and Metabolic Control in a Cohort of People With Diabetes: Retrospective Cohort Study. JMIR Diabetes, 8(1), e46880–e46880. https://doi.org/10.2196/46880

Amin, R., Ali, Y., Idrees, S., Bilal, A., Bushra Safeer, & Manzoor, A. (2024). The Role of Combination Therapies in Optimizing Diabetes Management. Indus Journal of Bioscience Research., 2(2), 582–588. https://doi.org/10.70749/ijbr.v2i02.244

Wright, E. E., & Subramanian, S. (2021). Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment. Diabetes Technology & Therapeutics, 23(S3), S-12-S-18. https://doi.org/10.1089/dia.2021.0191

Keyu, G., JiaQi, L., Liyin, Z., Jianan, Y., Li, F., Zhiyi, D., Qin, Z., Xia, L., Lin, Y.-W., & Zhiguang, Z. (2022). Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis. 10. https://doi.org/10.3389/fpubh.2022.990281

Kjölhede, K., Berntorp, K., Kristensen, K., Katsarou, A., Shaat, N., Wiberg, N., Knop, F. K., Kristensen, L. E., Dotevall, A., Elfvin, A., Sandgren, U., Sengpiel, V., & Englund‐Ögge, L. (2021). Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy – Pump vs multiple daily injections, a secondary analysis of an observational cohort study. Acta Obstetricia et Gynecologica Scandinavica, 100(5), 927–933. https://doi.org/10.1111/aogs.14039

Roze, S., Smith-Palmer, J., de Portu, S., Özdemir Saltik, A. Z., Akgül, T., & Deyneli, O. (2019). Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Diabetes Technology & Therapeutics, 21(12), 727–735. https://doi.org/10.1089/dia.2019.0198

Bosi, E., Choudhary, P., de Valk, H. W., Lablanche, S., Castañeda, J., de Portu, S., Da Silva, J., Ré, R., Vorrink-de Groot, L., Shin, J., Kaufman, F. R., Cohen, O., Laurenzi, A., Caretto, A., Slatterly, D., Henderson-Wilson, M., Weisnagel, S. J., Dubé, M.-C., Julien, V.-È., & Trevisan, R. (2019). Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. The Lancet Diabetes & Endocrinology, 7(6), 462–472. https://doi.org/10.1016/S2213-8587(19)30150-0

Teoh, I. H., Prabhu, J., Mubita, W., Azmi, S., Urwin, A., Doughty, I., Leelarathna, L., & Thabit, H. (2021). Real-Time Continuous Glucose Monitoring Benefits Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes Irrespective of Insulin Delivery Modality: Subanalysis of the MILLENNIAL Study. Journal of Diabetes Science and Technology, 16(1), 252–253. https://doi.org/10.1177/19322968211029627

Speight, J., Holmes-Truscott, E., Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Kerr, D., Flanagan, D., Heller, S. R., Evans, M. L., & Shaw, J. A. M. (2019). Satisfaction with the Use of Different Technologies for Insulin Delivery and Glucose Monitoring Among Adults with Long-Standing Type 1 Diabetes and Problematic Hypoglycemia: 2-Year Follow-Up in the HypoCOMPaSS Randomized Clinical Trial. Diabetes Technology & Therapeutics, 21(11), 619–626. https://doi.org/10.1089/dia.2019.0152

Yoo, J. H., & Kim, J. H. (2023). Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control. Korean Diabetes Journal, 47(1), 27–41. https://doi.org/10.4093/dmj.2022.0271

Moreno-Fernandez, J., López, L. M., Gomez, F. J., Pinés, P., Blanco, B., González, J., López, J., Herranz, S., Roa, C., & Gómez-Romero, F. J. (2020). Long-term effects of continuous subcutaneous insulin infusion in adults with type 1 diabetes mellitus patients: Results of a public healthcare system. Endocrinología, Diabetes Y Nutrición, 68(2). https://doi.org/10.1016/j.endinu.2019.10.011

Grace, T., & Slyer, J. (2021). Use of Real-Time Continuous Glucose Monitoring (rtCGM) Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy. Diabetes Technology & Therapeutics, 24(1). https://doi.org/10.1089/dia.2021.0212